An adaptive randomized clinical trial in interstitial cystitis/bladder pain syndrome evaluating efficacy of ASP3652 and the relationship between disease characteristics and Hunner’s lesions
World Journal of Urology, vol. 39, pp. 2065–2071
Authors 11
-
Affiliation as printed
Astellas Pharma Europe B.V, Leiden, The Netherlands
-
Astellas Pharma (Japan) · Astellas Pharma (Netherlands)
Affiliation as printed
Astellas Pharma Europe B.V, Leiden, The Netherlands. olivier.vantill@astellas.com
Astellas Pharma Inc, Medical & Development, Medical Specialties Therapeutic Area. 2-5-1, Nihonbashi-Honcho, Chuo-ku, Tokyo, 103-8411, Japan. olivier.vantill@astellas.com
Astellas Pharma Europe B.V, Leiden, The Netherlands
-
Affiliation as printed
Astellas Pharma Europe B.V, Leiden, The Netherlands
-
Affiliation as printed
Astellas Pharma Europe B.V, Leiden, The Netherlands
-
Affiliation as printed
Astellas Pharma Europe B.V, Leiden, The Netherlands
-
Affiliation as printed
Astellas Pharma Europe B.V, Leiden, The Netherlands
-
Affiliation as printed
Astellas Pharma Europe B.V, Leiden, The Netherlands
-
Affiliation as printed
Astellas Pharma Europe B.V, Leiden, The Netherlands
-
Affiliation as printed
Department of Urology, Queens University, Kingston, Canada
-
Affiliation as printed
Department of Urology, Stanford University, Stanford, CA, USA
-
Affiliation as printed
Department of Urology, University of Copenhagen, Copenhagen, Denmark
Cited by 15 stored of 15
15 results
No patents citing this paper on Lens.org (checked 2026-10-11).